These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
314 related items for PubMed ID: 17525656
1. Zymar (Gatifloxacin 0.3%) shows excellent Gram-negative activity against Serratia marcescens and Pseudomonas aeruginosa in a New Zealand White rabbit keratitis model. Mah FS, Romanowski EG, Kowalski RP, Yates KA, Gordon YJ. Cornea; 2007 Jun; 26(5):585-8. PubMed ID: 17525656 [Abstract] [Full Text] [Related]
2. The successful treatment of gatifloxacin-resistant Staphylococcus aureus keratitis with Zymar (gatifloxacin 0.3%) in a NZW rabbit model. Romanowski EG, Mah FS, Yates KA, Kowalski RP, Gordon YJ. Am J Ophthalmol; 2005 May; 139(5):867-77. PubMed ID: 15860293 [Abstract] [Full Text] [Related]
3. Comparison of besifloxacin, gatifloxacin, and moxifloxacin against strains of pseudomonas aeruginosa with different quinolone susceptibility patterns in a rabbit model of keratitis. Sanders ME, Moore QC, Norcross EW, Sanfilippo CM, Hesje CK, Shafiee A, Marquart ME. Cornea; 2011 Jan; 30(1):83-90. PubMed ID: 20847656 [Abstract] [Full Text] [Related]
4. Comparison of ophthalmic gatifloxacin 0.3% and ciprofloxacin 0.3% in healing of corneal ulcers associated with Pseudomonas aeruginosa-induced ulcerative keratitis in rabbits. Jensen H, Zerouala C, Carrier M, Short B. J Ocul Pharmacol Ther; 2005 Feb; 21(1):36-43. PubMed ID: 15718826 [Abstract] [Full Text] [Related]
6. A laboratory evaluation of antibiotic therapy for ciprofloxacin-resistant Pseudomonas aeruginosa. Rhee MK, Kowalski RP, Romanowski EG, Mah FS, Ritterband DC, Gordon YJ. Am J Ophthalmol; 2004 Aug; 138(2):226-30. PubMed ID: 15289131 [Abstract] [Full Text] [Related]
7. Treatment of experimental bacterial keratitis with topical trovafloxacin. Barequet IS, Denton P, Osterhout GJ, Tuli S, O'Brien TP. Arch Ophthalmol; 2004 Jan; 122(1):65-9. PubMed ID: 14718297 [Abstract] [Full Text] [Related]
8. A comparison of topical chlorhexidine, ciprofloxacin, and fortified tobramycin/cefazolin in rabbit models of Staphylococcus and Pseudomonas keratitis. Bu P, Riske PS, Zaya NE, Carey R, Bouchard CS. J Ocul Pharmacol Ther; 2007 Jun; 23(3):213-20. PubMed ID: 17593004 [Abstract] [Full Text] [Related]
9. Topical levofloxacin 1.5% overcomes in vitro resistance in rabbit keratitis models. Kowalski RP, Romanowski EG, Mah FS, Shanks RM, Gordon YJ. Acta Ophthalmol; 2010 Jun; 88(4):e120-5. PubMed ID: 20456251 [Abstract] [Full Text] [Related]
10. Fluoroquinolone therapy in a rabbit model of post-LASIK methicillin-resistant Staphylococcus aureus keratitis. Balzli CL, McCormick CC, Caballero AR, Huang B, Wigington L, Smith E, Tang A, O'Callaghan RJ. J Cataract Refract Surg; 2008 Feb; 34(2):295-301. PubMed ID: 18242457 [Abstract] [Full Text] [Related]
11. Efficacy of besifloxacin in a rabbit model of methicillin-resistant Staphylococcus aureus keratitis. Sanders ME, Norcross EW, Moore QC, Shafiee A, Marquart ME. Cornea; 2009 Oct; 28(9):1055-60. PubMed ID: 19724203 [Abstract] [Full Text] [Related]
18. Topical ciprofloxacin versus topical fortified antibiotics in rabbit models of Staphylococcus and Pseudomonas keratitis. Lauffenburger MD, Cohen KL. Cornea; 1993 Nov; 12(6):517-21. PubMed ID: 8261784 [Abstract] [Full Text] [Related]
19. Shifting trends in bacterial keratitis in south Florida and emerging resistance to fluoroquinolones. Alexandrakis G, Alfonso EC, Miller D. Ophthalmology; 2000 Aug; 107(8):1497-502. PubMed ID: 10919897 [Abstract] [Full Text] [Related]
20. Comparison of topical gatifloxacin 0.3% and ciprofloxacin 0.3% for the treatment of bacterial keratitis. Parmar P, Salman A, Kalavathy CM, Kaliamurthy J, Prasanth DA, Thomas PA, Jesudasan CA. Am J Ophthalmol; 2006 Feb; 141(2):282-286. PubMed ID: 16458681 [Abstract] [Full Text] [Related] Page: [Next] [New Search]